Genocea Biosciences (NASDAQ: GNCA) is one of 189 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Genocea Biosciences to related companies based on the strength of its profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.


This table compares Genocea Biosciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Genocea Biosciences N/A -591.07% -191.51%
Genocea Biosciences Competitors -4,553.30% -38.61% -42.12%

Volatility and Risk

Genocea Biosciences has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, Genocea Biosciences’ peers have a beta of 1.47, suggesting that their average stock price is 47% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Genocea Biosciences and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genocea Biosciences 0 2 3 0 2.60
Genocea Biosciences Competitors 573 2535 6796 134 2.65

Genocea Biosciences presently has a consensus price target of $7.38, suggesting a potential upside of 602.38%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.75%. Given Genocea Biosciences’ higher probable upside, equities analysts clearly believe Genocea Biosciences is more favorable than its peers.

Earnings & Valuation

This table compares Genocea Biosciences and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Genocea Biosciences $230,000.00 -$49.57 million -0.48
Genocea Biosciences Competitors $217.40 million -$39.40 million -61.88

Genocea Biosciences’ peers have higher revenue and earnings than Genocea Biosciences. Genocea Biosciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

34.7% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 6.7% of Genocea Biosciences shares are owned by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.


Genocea Biosciences peers beat Genocea Biosciences on 9 of the 13 factors compared.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual’s tumor.

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with's FREE daily email newsletter.